The 7-HOPE Alliance has reaffirmed the lawful status and scientific backing of 7-hydroxymitragynine (7-OH), countering claims by kratom advocacy groups with comprehensive legal and medical evidence. Legal experts have determined that 7-OH does not violate the US Food, Drug and Cosmetic Act, with the FDA not disputing this position. This legal standing creates significant implications for market regulation and consumer access to alternative wellness products.
Leading researchers from Johns Hopkins, Harvard, and UCLA have rejected safety concerns raised by opponents, finding no evidence of overdose deaths, respiratory depression, or widespread dependence associated with 7-OH. Toxicologists from UCLA and the Rocky Mountain Poison & Drug Center confirmed the absence of safety signals in national poison control databases despite millions of adult exposures. These findings directly challenge the narrative that 7-OH poses a public health risk.
Recent research published in Current Research in Structural Biology has revealed potential medical applications for 7-OH, demonstrating stable binding and favorable drug-likeness as potential HER2 inhibitors in breast cancer treatment. This early research suggests that scheduling 7-OH as a Schedule 1 controlled substance could eliminate promising pharmaceutical research opportunities.
The organization maintains that opposition campaigns are driven by market competition rather than consumer protection concerns. Jackie Subeck, Founder of 7-HOPE Alliance, stated that banning 7-OH would cause harm rather than prevent it, pushing people toward unsafe opioids and illicit markets. The alliance emphasizes that 7-OH offers more predictable dosing and a ceiling effect that limits opioid-like risks compared to high-dose mitragynine products.
Through its Save7OH.org campaign, the organization is gathering testimonials from veterans, chronic pain patients, and recovery individuals who rely on 7-OH for harm reduction. The group is working to expand scientific studies and ensure policymakers receive accurate information rather than what they describe as manufactured crisis narratives from competitors.
